Kathleen Colson

971 total citations
21 papers, 464 citations indexed

About

Kathleen Colson is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Kathleen Colson has authored 21 papers receiving a total of 464 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Hematology, 14 papers in Molecular Biology and 10 papers in Oncology. Recurrent topics in Kathleen Colson's work include Multiple Myeloma Research and Treatments (21 papers), Protein Degradation and Inhibitors (10 papers) and Cancer Treatment and Pharmacology (5 papers). Kathleen Colson is often cited by papers focused on Multiple Myeloma Research and Treatments (21 papers), Protein Degradation and Inhibitors (10 papers) and Cancer Treatment and Pharmacology (5 papers). Kathleen Colson collaborates with scholars based in United States, India and Australia. Kathleen Colson's co-authors include Paul G. Richardson, Kenneth C. Anderson, Joseph D Tariman, Linda Sun, E. M. O' Reilly, Justin L. Ricker, Constantine Mitsiades, Ivy Fearen, Syed Rizvi and Judy H. Chiao and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Supportive Care in Cancer.

In The Last Decade

Kathleen Colson

21 papers receiving 438 citations

Peers

Kathleen Colson
Nuriet K. Khuageva Russia
María-Victoria Mateos Spain
Eileen Liao United States
Jill N. Burke United States
Bonnie Jenkins United States
Serena Rocchi Italy
Lone S. Friis Denmark
Paul Schoen United Kingdom
Miguel Teodoro Hernández‐Garcia Spain
Robin Carson United States
Nuriet K. Khuageva Russia
Kathleen Colson
Citations per year, relative to Kathleen Colson Kathleen Colson (= 1×) peers Nuriet K. Khuageva

Countries citing papers authored by Kathleen Colson

Since Specialization
Citations

This map shows the geographic impact of Kathleen Colson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kathleen Colson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kathleen Colson more than expected).

Fields of papers citing papers by Kathleen Colson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kathleen Colson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kathleen Colson. The network helps show where Kathleen Colson may publish in the future.

Co-authorship network of co-authors of Kathleen Colson

This figure shows the co-authorship network connecting the top 25 collaborators of Kathleen Colson. A scholar is included among the top collaborators of Kathleen Colson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kathleen Colson. Kathleen Colson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Laubach, Jacob P., Sascha A. Tuchman, Jacalyn Rosenblatt, et al.. (2021). Phase 1 open-label study of panobinostat, lenalidomide, bortezomib + dexamethasone in relapsed and relapsed/refractory multiple myeloma. Blood Cancer Journal. 11(2). 20–20. 10 indexed citations
2.
Faiman, Beth, et al.. (2017). Renal, GI, and Peripheral Nerves: Evidence-Based Recommendations for the Management of Symptoms and Care for Patients With Multiple Myeloma. Clinical journal of oncology nursing. 21(5). 19–36. 7 indexed citations
3.
Noonan, Kimberly & Kathleen Colson. (2017). Immunomodulatory Agents and Proteasome Inhibitors in the Treatment of Multiple Myeloma. Seminars in Oncology Nursing. 33(3). 279–291. 9 indexed citations
4.
Kurtin, Sandra, et al.. (2016). Adherence, Persistence, and Treatment Fatigue in Multiple Myeloma. Journal of the Advanced Practitioner in Oncology. 7(2). 5 indexed citations
5.
Laubach, Jacob P., Sascha A. Tuchman, Jacalyn Rosenblatt, et al.. (2016). Phase 1b study of panobinostat in combination with lenalidomide, bortezomib, and dexamethasone in relapsed refractory multiple myeloma.. Journal of Clinical Oncology. 34(15_suppl). 8014–8014. 9 indexed citations
6.
Colson, Kathleen. (2015). Treatment-related symptom management in patients with multiple myeloma: a review. Supportive Care in Cancer. 23(5). 1431–1445. 34 indexed citations
7.
Richardson, Paul G., Jacob P. Laubach, Robert Schlossman, et al.. (2012). The potential benefits of participating in early‐phase clinical trials in multiple myeloma: long‐term remission in a patient with relapsed multiple myeloma treated with 90 cycles of lenalidomide and bortezomib. European Journal Of Haematology. 88(5). 446–449. 8 indexed citations
8.
Colson, Kathleen, et al.. (2011). Maintaining Bone Health in Patients With Multiple Myeloma. Clinical journal of oncology nursing. 15(0). 9–23. 28 indexed citations
9.
10.
Jakubowiak, Andrzej, Paul G. Richardson, Todd M. Zimmerman, et al.. (2010). Final Phase I Results of Perifosine In Combination with Lenalidomide and Dexamethasone In Patients with Relapsed or Refractory Multiple Myeloma (MM). Blood. 116(21). 3064–3064. 6 indexed citations
11.
Richardson, Paul G., Jacob P. Laubach, Constantine Mitsiades, et al.. (2010). Tailoring treatment for multiple myeloma patients with relapsed and refractory disease.. PubMed. 24(3 Suppl 2). 22–9. 10 indexed citations
12.
13.
Richardson, Paul G., Constantine Mitsiades, Kathleen Colson, et al.. (2008). Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma. Leukemia & lymphoma. 49(3). 502–507. 167 indexed citations
14.
Bilotti, Elizabeth, Kathleen Colson, Kathleen M. Curran, et al.. (2008). Management of Side Effects of Novel Therapies for Multiple Myeloma: Consensus Statements Developed by the International Myeloma Foundation's Nurse Leadership Board. Clinical journal of oncology nursing. 12(0). 9–12. 13 indexed citations
15.
Colson, Kathleen, et al.. (2008). Myelosuppression Associated With Novel Therapies in Patients With Multiple Myeloma: Consensus Statement of the IMF Nurse Leadership Board. Clinical journal of oncology nursing. 12(0). 13–20. 15 indexed citations
16.
Colson, Kathleen, Deborah Doss, Regina A. Swift, & Joseph D Tariman. (2008). Expanding Role of Bortezomib in Multiple Myeloma. Cancer Nursing. 31(3). 239–249. 7 indexed citations
17.
18.
Richardson, Paul G., Sundar Jagannath, Noopur Raje, et al.. (2007). Lenalidomide, Bortezomib, and Dexamethasone (Rev/Vel/Dex) in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Preliminary Results of a Phase II Study.. Blood. 110(11). 2714–2714. 22 indexed citations
19.
Richardson, Paul G., Constantine S. Mitsiades, Kathleen Colson, et al.. (2007). Final Results of a Phase I Trial of Oral Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) in Patients with Advanced Multiple Myeloma.. Blood. 110(11). 1179–1179. 16 indexed citations
20.
Richardson, Paul G., Sundar Jagannath, & Kathleen Colson. (2006). Optimizing the efficacy and safety of bortezomib in relapsed multiple myeloma.. PubMed. 4(5). 1; discussion 8; suppl 13–1; discussion 8; suppl 13. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Nuriet K. Khuageva Breakdown of academic impact, for papers by María-Victoria Mateos Breakdown of academic impact, for papers by Eileen Liao Breakdown of academic impact, for papers by Jill N. Burke Breakdown of academic impact, for papers by Bonnie Jenkins Breakdown of academic impact, for papers by Serena Rocchi Breakdown of academic impact, for papers by Lone S. Friis Breakdown of academic impact, for papers by Paul Schoen Breakdown of academic impact, for papers by Miguel Teodoro Hernández‐Garcia Breakdown of academic impact, for papers by Robin Carson
Rankless by CCL
2026